Germline activating mutations of the protein tyrosine phosphatase SHP2 (encoded by PTPN11), a positive regulator of the RAS signalling pathway 1 , are found in 50% of patients with Noonan syndrome 2 . These patients have an increased risk of developing leukaemia 3 , especially juvenile myelomonocytic leukaemia (JMML), a childhood myeloproliferative neoplasm (MPN). Previous studies have demonstrated that mutations in Ptpn11 induce a JMML-like MPN through cell-autonomous mechanisms that are dependent on Shp2 catalytic activity [4] [5] [6] [7] . However, the effect of these mutations in the bone marrow microenvironment remains unclear. Here we report that Ptpn11 activating mutations in the mouse bone marrow microenvironment promote the development and progression of MPN through profound detrimental effects on haematopoietic stem cells (HSCs). Ptpn11 mutations in mesenchymal stem/progenitor cells and osteoprogenitors, but not in differentiated osteoblasts or endothelial cells, cause excessive production of the CC chemokine CCL3 (also known as MIP-1α), which recruits monocytes to the area in which HSCs also reside. Consequently, HSCs are hyperactivated by interleukin-1β and possibly other proinflammatory cytokines produced by monocytes, leading to exacerbated MPN and to donorcell-derived MPN following stem cell transplantation. Remarkably, administration of CCL3 receptor antagonists effectively reverses MPN development induced by the Ptpn11-mutated bone marrow microenvironment. This study reveals the critical contribution of Ptpn11 mutations in the bone marrow microenvironment to leukaemogenesis and identifies CCL3 as a potential therapeutic target for controlling leukaemic progression in Noonan syndrome and for improving stem cell transplantation therapy in Noonansyndrome-associated leukaemias.
1
Germline activating mutations of the protein tyrosine phosphatase SHP2 (encoded by PTPN11), a positive regulator of the RAS signalling pathway 1 , are found in 50% of patients with Noonan syndrome 2 . These patients have an increased risk of developing leukaemia 3 , especially juvenile myelomonocytic leukaemia (JMML), a childhood myeloproliferative neoplasm (MPN). Previous studies have demonstrated that mutations in Ptpn11 induce a JMML-like MPN through cell-autonomous mechanisms that are dependent on Shp2 catalytic activity [4] [5] [6] [7] . However, the effect of these mutations in the bone marrow microenvironment remains unclear. Here we report that Ptpn11 activating mutations in the mouse bone marrow microenvironment promote the development and progression of MPN through profound detrimental effects on haematopoietic stem cells (HSCs). Ptpn11 mutations in mesenchymal stem/progenitor cells and osteoprogenitors, but not in differentiated osteoblasts or endothelial cells, cause excessive production of the CC chemokine CCL3 (also known as MIP-1α), which recruits monocytes to the area in which HSCs also reside. Consequently, HSCs are hyperactivated by interleukin-1β and possibly other proinflammatory cytokines produced by monocytes, leading to exacerbated MPN and to donorcell-derived MPN following stem cell transplantation. Remarkably, administration of CCL3 receptor antagonists effectively reverses MPN development induced by the Ptpn11-mutated bone marrow microenvironment. This study reveals the critical contribution of Ptpn11 mutations in the bone marrow microenvironment to leukaemogenesis and identifies CCL3 as a potential therapeutic target for controlling leukaemic progression in Noonan syndrome and for improving stem cell transplantation therapy in Noonansyndrome-associated leukaemias.
In our recent study investigating the potential effects of Ptpn11 activating mutations in neural cells, we used the Ptpn11 E76K mutation as a model and generated Ptpn11 E76K/+ Nestin-Cre + mice with Ptpn11 E76K mutation conditional knock-in mice (Ptpn11
E76K-neo/+
) 5 and NestinCre + mice. We inadvertently found that Ptpn11 E76K/+ Nestin-Cre + mice developed a myeloid malignancy resembling MPN at the age of 7 months or older as evidenced by splenomegaly, and significantly increased numbers of myeloid cells in the peripheral blood and myeloid progenitors in the bone marrow (BM) ( . 1d ) were significantly increased in these tissues. Moreover, extensive myeloid cell infiltration in the liver and lung was detected (Fig. 1b, Extended Data Fig. 1c) . The loxP-flanked neo cassette with a stop codon, which inactivated the targeted Ptpn11 E76K-neo allele 5 , was intact in the MPN cells of these mice (Fig. 1c) , indicating that the myeloid malignancy was not caused by the Ptpn11 mutation in haematopoietic cells. Previous studies have shown that Nestin is also expressed in BM mesenchymal stem/ progenitor cells (MSPCs) in addition to neural cells, and that perivascular Nestin + MSPCs constitute unique sinusoidal vascular and arteriolar HSC niches 8, 9 . We therefore examined targeted Ptpn11 alleles in BM-derived MSPCs and found that the inhibitory neo cassette was deleted in approximately 95% of these cells (Fig. 1c) . Interestingly, the frequency and absolute numbers of primitive haematopoietic progenitors and stem cells in the BM were markedly decreased in +/+ Nestin-Cre + mice were analysed. a, Spleen weights were determined (n = 17 mice per group). b, Cells isolated from BM, spleens, livers and lungs were assayed for Mac-1 + Gr-1 + myeloid cells by FACS (n = 12 mice per group). c, Genomic DNA isolated from BM haematopoietic cells and BM-derived MSPCs was assayed for the abundance of the neo cassette by qPCR (n = 5 mice per group). d-f, BM cells were assayed by multiparameter FACS to determine the pool size (n = 8 mice per group) (d), cell cycle distribution (n = 6 mice per group) (e), and intracellular signalling activities (n = 3 mice per group) (f) of HSCs (Lin -Sca-1 + c-Kit E76K/+ Nestin-Cre + mice. Recipients were monitored for MPN development for 6-8 months. Data shown in a-f are mean ± s.d. of all mice examined; *P < 0.05; **P < 0.01; ***P < 0.001. Source Data for this figure are available online. 
Ptpn11
E76K/+ Nestin-Cre + mice, whereas these cells in the spleen were increased (Fig. 1d, Extended Data Fig. 1e-g ). The fact that the numbers of mature myeloid cells and myeloid progenitors increased whereas stem cells decreased implied aberrant activation and accelerated differentiation of HSCs in the BM. Indeed, the number of quiescent HSCs in the G 0 phase in Ptpn11 E76K/+ Nestin-Cre + mice decreased by twofold, whereas that of HSCs in the G 1 or S/G 2 /M phases doubled (Fig. 1e) . HSCs in these mice had reduced apoptosis (Extended Data Fig. 1h ). Assessment of intracellular signalling activities demonstrated that Erk, Akt and NF-κ B pathways were highly activated in the HSCs of Ptpn11 E76K/+ Nestin-Cre + mice (Fig. 1f) . The MPN developed in chronicphase Ptpn11 E76K/+ Nestin-Cre + mice was not transferable to wild-type transplants, but MPN cells from terminally ill mice reproduced the same disease in 50% of the recipients (Fig. 1g) (Fig. 2d ). The differences in the severity and prognosis of MPN between these two lines of mice do not appear to be associated with pI-pC administration or the times/stages when the disease mutations were induced (Extended Data Fig. 2b-e (Fig. 2g, h ). Similar results were obtained from the Noonan syndrome mutation Ptpn11 D61G global knock-in mice, which were born with a developmental disorder resembling Noonan syndrome and developed JMML-like MPN 4 . Transplantation of wild-type BM cells into lethally-irradiated Ptpn11 D61G/+ mice initially reversed MPN. The mice appeared to be cured during the first 3 months after transplantation, but 8 out of 14 then developed donor-cell-derived MPN in the next 5 months (Extended Data Fig. 3c ).
To further define the cell types in the Ptpn11-mutated BM microenvironment that have an important role in driving/enhancing MPN development, we generated cell-type-specific Ptpn11 E76K/+ knock-in mice and monitored them for one and a half years. The Ptpn11 ), but not Osteocalcin (Oc)-expressing differentiated osteoblasts or VE-cadherin-expressing endothelial cells, induced MPN (Table 1 , Extended Data Fig. 4a, b) . The deletion efficiency of neo from mutated Ptpn11 alleles in MSPCs generally correlated with the latency and severity of MPN that developed in these lines of cell-type-specific mutant mice (Extended Data Fig. 4c ), suggesting that MSPCs and/or osteoprogenitors were responsible for the leukaemogenic effects of the Ptpn11-mutated BM microenvironment. HSCs were hyperactivated only in the lines of mice that developed MPN (Table 1) , further underscoring the effect of HSC hyperactivation on the myeloid malignancy induced/enhanced by the Ptpn11 mutation in MSPCs and osteoprogenitors.
We next sought to identify the mechanisms by which Ptpn11-mutated MSPCs and osteoprogenitors activate HSCs (wild type or mutant with the same Ptpn11 mutation). Compared to wild-type HSCs, Ptpn11 E76K/+ mutant HSCs had accelerated myeloid differentiation owing to cell autonomous effects 5 , regardless of whether they were co-cultured with wild-type or Ptpn11 E76K/+ BM stromal cells or MSPCs (Extended Data Fig. 5a ). Unexpectedly, Ptpn11 E76K/+ stromal cells and MSPCs had no significant activating effects on either Ptpn11 E76K/+ or wild-type HSCs (Extended Data Fig. 5a ). Similar results were obtained when HSCs and MSPCs were co-cultured in two separate chambers that still allowed growth factors/cytokines to freely cross (Extended Data Fig. 5b ). Interestingly, cytokine-chemokine array analyses for the BM plasma revealed that proinflammatory cytokines IL-1β and TREM-1, but not IL-6 (refs 16, 17), G-CSF 18, 19 , GM-CSF 16 , TNF-α 17, 19, 20 , or IL-1α 17 that are known to be involved in MPN, were substantially increased in Ptpn11 E76K/+ Mx1-Cre + mice (Fig. 3a) . In addition, the inflammatory CC chemokine CCL3 and TIMP-1, an inhibitor of matrix metalloproteinases generated by monocytes 21 , were increased, Cell-type-specific Ptpn11 E76K knock-in mice as indicated were generated and monitored for MPN development for up to 18 months. The incidence of MPN, cycling status of BM HSCs, and spleen weights of the animals euthanized at the indicated ages were determined. +/+ Mx1-Cre + mice (n = 3 mice per group) 12 weeks after pI-pC administration (a) and the culture medium of MSPCs derived from these mice (b). Representative results are shown. c, BM plasma collected from the indicated cell-type-specific Ptpn11 E76K/+ knock-in mice (7-8 months old; n = 3 mice per group) was assayed for the levels of IL-1β and CCL3 by ELISA. d, CCL3 levels in the culture medium of MSPCs derived from the indicated lines of Ptpn11 E76K/+ knock-in mice (n = 3 mice per group) were determined by ELISA. e, Levels of IL-1β , CCL3, IL-6 and G-CSF produced by cells from patients with JMML with the indicated PTPN11 mutations, and healthy human apheresis or BM cells were determined by cytometric bead array assay. f, CCL3 and CXCL12 levels in the culture medium of MSPCs derived from patients with Noonan syndrome (NS) with the indicated PTPN11 mutations or healthy individuals were determined by cytometric bead array and ELISA assays, respectively. Each bar in e, f represents one patient or healthy individual. Data shown in c, d are mean ± s.d. of all mice examined. Statistical significance was determined between the indicated cell-type-specific Ptpn11 E76K/+ knock-in mice and Ptpn11 +/+ Nestin-Cre + control mice; *P < 0.05; **P < 0.01; ***P < 0.001. Source Data for this figure are available online. whereas CXCL12 (SDF-1), a chemokine important for HSC retention in the niche 22, 23 , was decreased (Fig. 3a) . The spleen plasma from Ptpn11 E76K/+ Mx1-Cre + mice also showed markedly increased levels of CCL3, CCL12 and CCL4 (Extended Data Fig. 6a ).
To comprehensively identify the protein factors that were aberrantly produced by MSPCs with Ptpn11 mutations, we performed RNA-sequencing gene expression profiling analyses (GEO number GSE81311). mRNA levels of Ccl3, Ccl12, and Ccl4 were increased by 6.5-, 3.7-, and 1.7-fold (log 2 scale), respectively, whereas expression of Cxcl12 was decreased by 1.8-fold in Ptpn11 E76K/+ MSPCs (Extended Data  Fig. 6b ). In addition, the anti-inflammatory cytokine IL-1 receptor antagonist (Il1ra), was also increased by 4.6-fold. Cytokine-chemokine array analyses with MSPC culture medium confirmed that the amount of CCL3, CCL12, and IL-1ra proteins secreted by Ptpn11 E76K/+ MSPCs was indeed greatly increased (Fig. 3b) . Levels of IL-1β and CCL3 in the BM plasma (Fig. 3c) and CCL3 in the culture medium of MSPCs (Fig. 3d ) isolated from microenvironmental cell-type-specific Ptpn11 E76K/+ mice correlated closely with the latency and incidence of MPN in these lines of mice. Remarkably, IL-1β production from PTPN11-mutated leukaemic cells from patients with JMML also increased by 7.9-fold to 65.7-fold over that of healthy donor cells (Fig. 3e) . The amount of CCL3 produced by MSPCs derived from PTPN11-mutation-positive Noonan syndrome patients with JMML complications increased by 3.3-fold to 43.0-fold, whereas CXCL12 was decreased compared to those secreted by normal human MSPCs (Fig. 3f) . The direct effects of these aberrantly produced cytokines/chemokines on HSCs were then determined. Interestingly, although IL-1β robustly activated HSCs to differentiate towards myeloid cells and monocytes, CCL3, CCL4, and CCL12-which were over-produced by Ptpn11-mutated MSPCs-did not show any activating effects on HSCs (Extended Data Fig. 6c) .
We next investigated the in vivo consequences of the excessive CC chemokines produced by Ptpn11-mutated MSPCs. Nestin + MSPCs and Osteopontin + osteoblasts were increased in Ptpn11 Data Fig. 7a ). Frequencies of colony-forming unit fibroblasts (CFU-F) in the BM, indicative of MSPCs, were increased to various extents (Extended Data Fig. 7b ) that were commensurate with the induction efficiencies of the Ptpn11 E76K/+ mutation in MSPCs in various lines of microenvironmental cell-type-specific knock-in mice (Extended Data Fig. 4c) . Indeed, MSPCs isolated from Ptpn11 E76K/+ Nestin-Cre + mice grew much faster with significantly enhanced cycling due to elevated cell signalling activities caused by the activating mutation of Shp2 (Extended Data Fig. 7c-e) . In addition, osteogenesis was enhanced in Ptpn11 E76K/+ Nestin-Cre + mice as evidenced by markedly increased thickness of the calvarium (Fig. 4a) Fig. 8b ). This was probably attributable to the excessive CCL3 and possibly other CC chemokines secreted from Ptpn11 E76K/+ MSPCs, because these chemokines strongly induce chemotaxis of monocytes 24, 25 . Consequently, the percentage of HSCs surrounded by CD115 + Gr-1 + monocytes greatly increased (Fig. 4c ) Mice were killed, and spleens were weighted (n = 5 and 10 mice for the antagonist and vehicle groups, respectively) (e). White blood cell counts in the peripheral blood were determined at the indicated time points (n = 5 mice per group, each line represents one mouse) (f). Myeloid cells (Mac-1 + Gr-1 + ) in the BM, spleen, and peripheral blood (PB) (n = 5 and 10 mice for the antagonist and vehicle groups, respectively) (g), and the cell cycle distribution of HSCs in the BM (n = 5 and 6 mice for the antagonist and vehicle groups, respectively) (h) were determined at the end of the experiments. Representative images are shown in a-d. Data shown in e, g, and h are mean ± s.d. of all mice examined; **P < 0.01; ***P < 0.001. Source Data for this figure are available online. and the percentage of HSCs close to Nestin + MSPCs decreased (Fig. 4d) . Furthermore, the distance of HSCs from CD31 +
CD144
+ endothelial cells doubled (Extended Data Fig. 8c ) and the percentage of HSCs residing in the megakaryocyte niches significantly decreased (Extended Data Fig. 8d ) in Ptpn11 E76K/+ Nestin-Cre + mice. Thus, it appears that persistent high levels of proinflammatory cytokines produced by the monocytes (with or without the Ptpn11 mutation) recruited by Ptpn11-mutated MSPCs/osteoprogenitors hyperactivated neighbouring HSCs with the same mutation or wild-type donor HSCs and displaced them from MSPC, endothelial cell, and megakaryocyte niches that are essential for maintaining HSC dormancy 8, 9, [26] [27] [28] [29] , resulting in exacerbated MPN or donor-cell-derived MPN.
To validate the role of excessive CCL3 in mediating the pathogenic effects of the Ptpn11-mutated BM microenvironment, we treated Ptpn11 
Mx1-Cre
+ mice with CCL3 receptor antagonists. Similar effects, but to a lesser extent, were observed (Extended Data Fig. 10a-e) .
In summary, our mouse genetics studies have demonstrated that Ptpn11 mutations in the BM microenvironment have pathogenic effects on resident HSCs, promoting/inducing leukaemogenesis. Nevertheless, as Noonan syndrome involves various mutations in PTPN11 and other genes (such as RAS, CBL, B-RAF, SOS1, and SHOC2), it remains to be determined whether the leukaemogenic effects of microenvironmental PTPN11 mutations depend on the potencies of these mutations, and whether Noonan-syndrome-associated mutations in other genes in the BM microenvironment also have detrimental effects. Clinical phenotypegenotype correlative studies in a large cohort of Noonan syndrome patients are required to address these questions.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. . A neo cassette with a stop codon flanked by loxP sites was inserted in the second intron of the Ptpn11 allele followed by the mutation GAA (E) to AAA (K) at the amino acid 76 encoding position in the third exon. The mice were backcrossed to C57BL/6 mice for more than ) collected from indicated donor mice were transplanted into lethally irradiated (1,100 cGy) recipient mice with the indicated genotypes through tail vein injection. Recipients were monitored for MPN development for 6-8 months.
Quantitative real-time PCR (qPCR).
To determine the abundance of the neo cassette in the targeted Ptpn11 allele, genomic DNA of haematopoietic cells, MSPCs, or other indicated cells was extracted with a ZR-Duet DNA/RNA MiniPrep extraction kit (Zymo Research). The abundance of the neo cassette was then quantified by qPCR using the Applied Biosystems 7500 Fast Real-Time PCR System. The PCR primers used were: 5′ -TGGGAAGACAATAGCAGGCA-3′ and 5′ -CCCACTCA CCTTGTCATGTA-3′ .
Fluorescence-activated cell sorting (FACS).
The pool size, cell cycle status, apoptosis, and cell signalling activities of HSCs were analysed by multiparameter FACS analyses, as previously described 38 . In brief, for the HSC-pool-size analysis, fresh BM cells were stained with the following antibodies (eBiosciences, San Diego, unless otherwise noted): lineage antibodies (B220 (RA3-6B2), CD3 (145-2C11), Gr-1 (RB6-8C5), Mac-1 (M1/70), and Ter-119 (TER-119)), antiSca-1 (D7, BD Biosciences), anti-c-Kit (2B8), anti-CD150 (TC15-12F12.2, BD Biosciences), anti-CD48 (HM48-1), and anti-Flk2 (A2F10.1). Lin -Sca-1 + cKit
Flk2
-cells were quantified as HSCs. For the cell cycle analysis, freshly collected BM cells were stained for HSCs as above. Cells were then fixed and permeabilized using a Cytofix/Cytoperm kit (BD Biosciences), stained with Ki-67 antibody, and further incubated with Hoechest 33342 (20 μ g ml -1 ). For the apoptosis analysis, BM cells were stained for HSCs, and then incubated with Annexin V and 7-amino-actinomycin D (BD Biosciences). For cell signalling analyses, BM cells were stained for HSCs, fixed and permeabilized using a Cytofix/ Cytoperm kit, and then stained with anti-phospho-Erk (mouse IgG) (E-4, Santa Cruz Biotechnology), anti-phospho-Akt (rabbit IgG) (C31E5E, Cell Signaling), or anti-phospho-NF-κ B (rabbit IgG) (93H1, Cell Signaling) antibodies, washed and further incubated with AlexaFluor488-conjugated secondary antibodies (goat antimouse IgG or goat anti-rabbit IgG) (Life technologies). Phosphorylation levels of these signalling proteins were determined by mean fluorescence intensities (MFI) of gated cells. Data were collected on BD LSR II Flow Cytometer (BD Biosciences) and analysed with FlowJo (Treestar). In vitro HSC culture. HSCs (Lin . In brief, BM was collected from long bones. The bones were then crushed and digested with collagenase type II (2.5 mg ml -1 ) (Worthington Biochemical Corporation). BM cells and digested bone fragments were combined and cultured in DMEM supplemented with 15% fetal bovine serum (FBS). For human MSPC derivation, only BM cells were used. Suspension haematopoietic cells were removed after 24 h. Medium was replenished every 72 h. Colonies of MSPCs appeared 6-8 days after initial plating. To further purify MSPCs, cells were collected and stained with biotin-conjugated CD45 antibody and anti-biotin microbeads. CD45
+ haematopoietic cells were depleted using MACS separation columns (Miltenyi Biotec Inc.). The purity of MSPCs (> 95%) was further confirmed according to the (CD45 ) were seeded in 0.9% methylcellulose IMDM medium containing 30% FBS, glutamine (10
, and IL-3 (1 ng ml
). After 7 days of culture at 37 °C in a humidified 5% CO 2 incubator, colonies (primarily CFU-GM) formed by more than 50 haematopoietic cells were counted under an inverted microscope. RNA-sequencing analysis. MSPCs (CD45 -Ter-119
were freshly isolated from the BM of Ptpn11 E76K/+ Nestin-Cre + and Ptpn11
+/+
Nestin-Cre + mice. RNA was extracted using the RNeasy Midi kit (Qiagen). Total RNA samples were enriched for polyadenylated transcripts using the Oligotex mRNA Mini kit (Qiagen), and strand-specific RNA-seq libraries were generated using PrepX RNA library preparation kits (IntegenX), following the manufacturer's protocol. After cleanup with AMPure XP beads (Beckman Coulter) and amplification with Phusion High-Fidelity polymerase (New England BioLabs), RNA libraries were sequenced on a HiSeq 4000 instrument to a depth of at least 20 million reads. The correlation coefficient between the two groups is 0.954, which verifies that the method is accurate (Extended Data Fig. 6b ). Before differential gene expression analysis, for each sequenced library, the read counts were adjusted by edgeR program package through one scaling normalized factor. Differential expression analysis of two conditions was performed using the DEGSeq R package (1.12.0). The P values were adjusted using the Benjamini-Hochberg method. Corrected P value of 0.005 and log 2 (fold change) of 1 were set as the threshold for significantly different expression. Chemokine-cytokine array analyses. Femurs were dissected from Ptpn11 E76K/+ Mx1-Cre + mice and Ptpn11
Mx1-Cre + littermates 12 weeks after pI-pC administration. BM plasma was collected by flushing one femur with 1.0 ml of phosphate buffered saline (PBS). MSPCs derived from pI-pC-administered Ptpn11 E76K/+ Mx1-Cre + and Ptpn11 +/+ Mx1-Cre + mice were cultured (4 × 10 6 cells in 2.0 ml medium) in serum-free DMEM for 48 h. The culture medium was then collected. BM plasma or MSPC culture medium were analysed with Mouse Cytokine Antibody Array blots (R&D Systems) following the instructions provided by the manufacturer. ELISA and cytometric bead array assay. BM plasma collected from one femur and one tibia in 500 μ l PBS. Culture medium was collected from mouse MSPCs (4 × 10 6 cells per 2.0 ml) at second or third passages cultured in serum-free DMEM for 48 h. These samples were assayed for levels of IL-1β and CCL3 using enzyme-linked immunosorbent assay (ELISA) kits (IL-1β : eBioscience; CCL3: R&D Systems) following the instructions provided by the manufacturers. To determine multiple cytokines/chemokines produced by human MSPCs, MSPCs (2 × 10 4 cells ml ) for 72 h. The culture medium was then collected and cytokine/chemokine levels were determined by the BD Cytometric Bead Array Flex Sets (BD Biosciences) following the manufacturer's instructions. Human CXCL12 levels in MSPC culture medium were measured using a Human CXCL12/SDF-1 alpha Quantikine ELISA Kit (R&D systems). Immunofluorescence staining. Frozen tissue sections prepared from 4% paraformaldehyde-fixed and decalcified bones were thawed at room temperature and then rehydrated with PBS. The slides were stained with the following antibodies letter reSeArCH To determine statistical significance in the incidences of MPN development and malignant progression, Fisher's exact tests were performed. *P < 0.05; **P < 0.01; *** P < 0. +/+ Nestin-Cre + littermates (n = 4 mice per group) were assayed as above. Data shown in a, b, d-j are mean ± s.d. of all mice examined; *P < 0.05; **P < 0.01; ***P < 0.001. Source Data for this figure are available online. E76K/+ Vav1-Cre + (n = 7 mice) mice at the same age were monitored at the indicated time points. Data shown in b-e are mean ± s.d. of all mice examined; **P < 0.01; ***P < 0.001; N.S., not significant. Source data are available online. 
